Targovax ASA: Fourth quarter 2020 results
Oslo, Norway, 18 February 2021 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its fourth quarter 2020 results. Targovax will host a Capital Markets Day for investors, analysts and the press at 14:30 CET today, which will include a fourth quarter update (details below).FOURTH QUARTER HIGHLIGHTS DATA · Announced impressive objective responses as well as effects on non-injected lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients · Demonstrated encouraging